Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Pharmacol Ther. 2017 Feb 7;173:159–170. doi: 10.1016/j.pharmthera.2017.02.014

Figure 2. Inhibition of receptor kinases via ligand-binding site inhibition.

Figure 2

Receptor kinases can be activated by extracellular signals that bind the ectodomain of the kinase. These extracellular ligand-binding sites can be selectively targeted to ultimately inhibit kinase activation. Examples include the interaction between PDGF and PDGFR, EGF and EGFR, HGF and the Met receptor and VEGF and VEGFR.